Related Experiment Video

Updated: Dec 11, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.1K

Drug-eluting stents in diabetic patients: Are we still treading water?

Mauro Chiarito1,2, Roxana Mehran1

  • 1Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|August 16, 2020
PubMed

Insights

Diabetic patients with coronary artery disease (CAD) face higher risks after drug-eluting stent (DES) implantation. While DES show similar outcomes, specific improvements are needed for diabetic patients, particularly those on insulin.

Area of Science:

  • Cardiology
  • Endocrinology
  • Medical Devices

Background:

  • Diabetic patients have a higher prevalence and risk of adverse events associated with coronary artery disease (CAD).
  • Drug-eluting stents (DES) are commonly used for CAD treatment, but their comparative safety and efficacy in diabetic versus nondiabetic populations remain debated.
  • This study investigates the 3-year outcomes of different DES implantation strategies in a large cohort of diabetic and nondiabetic patients.

Discussion:

  • The registry demonstrated similar overall 3-year clinical outcomes for various DES types in both diabetic and nondiabetic patients.
  • However, diabetic patients, especially those requiring insulin therapy, exhibited a significantly elevated risk of adverse events compared to their nondiabetic counterparts.
  • These findings highlight persistent disparities in CAD management outcomes despite advancements in DES technology.

Key Insights:

  • DES implantation shows comparable safety and efficacy across different types in diabetic and nondiabetic patients over 3 years.
  • Diabetic patients, particularly insulin-treated individuals, experience a higher incidence of adverse events post-DES implantation.
  • Current DES performance is insufficient to fully mitigate the heightened risks faced by diabetic patients with CAD.

Outlook:

  • Further research and development are essential to enhance DES performance specifically for the diabetic population.
  • Tailored strategies and novel stent designs may be required to address the unmet needs of diabetic patients with CAD.
  • Improving DES efficacy in diabetics is crucial for reducing CAD-related adverse events and optimizing patient outcomes.

More Related Videos

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis08:26

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

7.1K
Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

11.9K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
439
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.6K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
158
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
474